You just read:

DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)

News provided by

DelMar Pharmaceuticals, Inc.

May 08, 2017, 08:30 ET